News for Revolution Medicines, Inc. (RVMD)

**media[589978,589979]**

Health insurers rally after CMS increases payment to Medicare Advantage plans. Nvidia closes deal to acquire startup Lepton AI. China pledges to 'fight to the end' against new U.S. tariffs.

We recently compiled a list of the 10 Best Debt Free Mid Cap Stocks to Buy Now. In this article, we are going to take a look at where Revolution Medicines, Inc.

We recently published a list of the 10 Best Mid Cap Biotech Stocks to Buy. In this article, we are going to take a look at where Revolution Medicines, Inc.

We recently published a list of the 10 Best Mid Cap Biotech Stocks to Buy. In this article, we are going to take a look at where Revolution Medicines, Inc. (NASDAQ:RVMD) stands against the other best mid cap biotech stocks to buy. Is the Biotech Sector Oversaturated? On March 6, Jared Holz, Mizuho health care […]

We recently compiled a list of the 10 Cash-Rich Mid Cap Stocks To Buy Now. In this article, we are going to take a look at where Revolution Medicines, Inc.

Revolution Medicines Inc's innovative approach to targeting RAS and mTOR signaling pathways in precision oncology.Challenges of operating in a highly competiti

Revolution Medicines, Inc. (NASDAQ:RVMD) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ETCompany ParticipantsRyan Asay - Senior Vice...

**media[552061]**

”“ TNG462 granted Orphan Drug Designation for treatment of pancreatic cancer ”“ ”“ Investigational New Drug (IND) application for TNG456, a next-generation

Cash and Investments: $2.3 billion at the end of Q4 2024, including $823 million from an equity offering.R&D Expenses: $188.1 million for Q4 2024, up from $148

Feb 26, 2025 / 09:30PM GMTOperator Good day, and thank you for standing by. Welcome to the Revolution Medicines Q4 2024 earnings conference call. (Operator Inst

Revolution Medicines Inc (RVMD), a late-stage clinical oncology company, released its financial results for the quarter and full year ending December 31, 2024,

Company anticipates substantially completing enrollment this year in ongoing Phase 3 RASolute 302 trial of daraxonrasib in previously treated metastatic pancrea

**media[551509]**

Revolution Medicines Inc (RVMD) is set to release its Q4 2024 earnings on Feb 26, 2025. The consensus estimate for Q4 2024 revenue is $0.35 million, and the ear

REDWOOD CITY, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. ( RVMD), a late-stage clinical oncology company developing novel targeted t

Buying stocks that sell for 100 times revenue or more means facing terrible odds. Of 84 such stocks covered in this column, 60 have declined within a year.

Significant Stock Acquisition by Paradigm Biocapital Advisors LP (Trades, Portfolio) On December 31, 2024, Paradigm Biocapital Advisors LP (Trades, Portfolio) e